Veeda Clinical Research
7
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
43%
3 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )
Role: collaborator
Efficacy and Safety of VA106483 in Elderly Males
Role: collaborator
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Role: collaborator
Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life
Role: collaborator
Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients
Role: collaborator
Treatment of Symptoms in Male Patients With Lower Urinary Tract Symptoms (LUTS) Predominant Storage Symptoms (Overactive Bladder Syndrome)
Role: collaborator
First Administration to Man Of Org 25435 a New Intravenous Anesthetic
Role: collaborator
All 7 trials loaded